British Columbia Cancer Agency Agrees to Fund Genomic Health's Oncotype DX | GenomeWeb

NEW YORK (GenomeWeb) ─ The British Columbia Cancer Agency has agreed to reimburse for Genomic Health's Oncotype DX breast cancer recurrence test.

The multi-gene expression diagnostic is available in four other Canadian provinces in addition to British Columbia, including Ontario, Quebec, Saskatchewan, and Newfoundland.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.